Vasomune Therapeutics Receives Funding Assistance to Advance Its Dual-Use Vascular Leak Therapy

Funding will accelerate development of Pegevongitide (AV-001), Vasomune’s lead therapy targeting vascular leak, for dual-use applications TORONTO — Vasomune Therapeutics, Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing therapies that target endotheliopathy to prevent and reverse vascular leak, today announced that it is receiving advisory services and research and development funding of up to $280,347, through […]